Torsdag 26 December | 16:01:50 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-10-28 07:00 Kvartalsrapport 2025-Q3
2025-08-14 07:00 Kvartalsrapport 2025-Q2
2025-06-04 N/A Årsstämma
2025-04-30 07:00 Kvartalsrapport 2025-Q1
2025-02-12 18:00 Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-06-05 - X-dag ordinarie utdelning NAVA 0.00 NOK
2024-06-04 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-08-11 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning NAVA 0.00 NOK
2023-06-01 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-12 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning NAVA 0.00 NOK
2022-06-02 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-06-04 - X-dag ordinarie utdelning NAVA 0.00 NOK
2021-06-03 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-06 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-04 - X-dag ordinarie utdelning NAVA 0.00 NOK
2020-06-03 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-03-11 - Extra Bolagsstämma 2020
2020-02-13 - Bokslutskommuniké 2019
2019-11-01 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-29 - X-dag ordinarie utdelning NAVA 0.00 NOK
2019-05-28 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-12-20 - Extra Bolagsstämma 2018
2018-11-09 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-06-08 - X-dag ordinarie utdelning NAVA 0.00 NOK
2018-06-07 - Årsstämma
2018-05-30 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-07-28 - Kvartalsrapport 2017-Q2
2017-06-07 - X-dag ordinarie utdelning NAVA 0.00 NOK
2017-06-06 - Årsstämma
2017-05-10 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2017-01-13 - Extra Bolagsstämma 2017
2016-11-11 - Kvartalsrapport 2016-Q3
2016-08-18 - Kvartalsrapport 2016-Q2
2016-06-21 - X-dag ordinarie utdelning NAVA 0.00 NOK
2016-06-20 - Årsstämma
2016-05-11 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-10-30 - Extra Bolagsstämma 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-21 - Kvartalsrapport 2015-Q2
2015-06-09 - X-dag ordinarie utdelning NAVA 0.00 NOK
2015-06-08 - Årsstämma
2015-04-28 - Kvartalsrapport 2015-Q1
2015-02-27 - Bokslutskommuniké 2014
2014-10-31 - Kvartalsrapport 2014-Q3
2014-08-22 - Kvartalsrapport 2014-Q2
2014-06-10 - Årsstämma
2014-05-06 - Kvartalsrapport 2014-Q1
2014-02-27 - Bokslutskommuniké 2013
2013-11-01 - Kvartalsrapport 2013-Q3
2013-08-30 - Kvartalsrapport 2013-Q2
2013-06-13 - Kapitalmarknadsdag 2013
2013-05-23 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-15 - Bokslutskommuniké 2012
2012-02-10 - Bokslutskommuniké 2011
2011-10-21 - Kvartalsrapport 2011-Q3
2011-08-25 - Kvartalsrapport 2011-Q2
2011-05-05 - Kvartalsrapport 2011-Q1
2011-04-14 - Årsstämma
2011-02-04 - Bokslutskommuniké 2010
2010-10-28 - Kvartalsrapport 2010-Q3
2010-08-26 - Kvartalsrapport 2010-Q2
2010-05-05 - Kvartalsrapport 2010-Q1
2010-03-25 - Årsstämma
2010-02-11 - Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Navamedic är ett nordiskt läkemedelsföretag som levererar läkemedel, OTC, medicinska nutritionsprodukter för sällsynta diagnoser samt medicintekniska produkter till sjukhus och apotek inom områden som exempelvis obesitas, kvinnohälsa, urologi, mage/tarm, samt smärta. Navamedic verkar i de nordiska länderna, Baltikum och Benelux men är även representerade i Storbritannien och Grekland. Bolaget etablerades 1999 med säte i Oslo.
2023-11-01 08:00:00

Oslo, 1 November 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the third quarter of 2023. With growth across the company's three core product areas, Prescription Drugs (RX), Consumer Health and Hospital, year to date, Navamedic has delivered another record quarter. Revenues for the third quarter amounted to NOK 141 million, corresponding to a 51.9 per cent increase Year-over-Year.

The company's gross margin was 37.6 per cent, down from 42.5 per cent in the third quarter of 2022. Adjusted EBITDA (EBITDA less acquisition cost) amounted to NOK 17.4 million, up from NOK 12.7 million in the corresponding quarter of 2022. Operating results (EBIT) amounted to NOK 12.7 million, compared to NOK 10.9 million in the same period last year.

"Over the last few months, we have demonstrated that consistent and disciplined execution of our strategy can produce significant revenue growth. It is also the first quarter where we see the YoY effect of the products acquired through Impolin. With a broad customer base across our three product areas, we have managed to maintain growth and gain traction in new and existing markets. Today's broad product portfolio also enable us to offer treatments to patients suffering from a variety of illnesses and disorders, from Parkinson's disease and obesity to gastro and pain," commented Kathrine Gamborg Andreassen, CEO of Navamedic.

During the quarter, Navamedic has shown that the path to becoming a NOK 1 billion revenue company is within reach. Moving forward, the company plans to continue growing through M&A and to proactively seek opportunities to secure and increase the portfolio value through the in-licensing and out-licensing of products and brands whilst exploring growth opportunities in additional markets worldwide.

Following the acquisition of Sensidose AB, the company has established a commercial strategy for Flexilev (Myfid), starting with a commercial launch in Norway and Denmark. Flexilev (Myfid) currently has marketing authorisation in a total of 10 countries and is reimbursed in all of the Nordic countries. 

Navamedic will present the third quarter 2023 results at 08.30 today. The presentation will take place at Haakon VIIs gate 2 in Oslo, and will be available to follow via webcast at the following link: https://navamedic.com/investors/financial-results/

Representatives from Navamedic's management team, CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation.

EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached third-quarter presentation on slide 22.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.